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Abstract
Background: It is not clear if point-of-care (POC) testing 
for hemoglobin A1c (HbA1c) is associated with glycemic 
control in type 2 diabetes.
Methods: In this cross-sectional study, we linked general 
practitioner (GP) data on 22,778  Norwegian type 2 dia-
betes patients to data from the Norwegian Organization 
for Quality Improvement of Laboratory Examinations. 
We used general and generalized linear mixed models to 
investigate if GP offices’ availability (yes/no) and analyti-
cal quality of HbA1c POC testing (average yearly “trueness 
score”, 0–4), as well as frequency of participation in HbA1c 
external quality assurance (EQA) surveys, were associated 
with patients’ HbA1c levels during 2014–2017.
Results: Twenty-eight out of 393 GP offices (7%) did 
not perform HbA1c POC testing. After adjusting for 
confounders, their patients had on average 0.15% 
higher HbA1c levels (95% confidence interval (0.04–0.27) 
(1.7 mmol/mol  [0.5–2.9]). GP offices participating in one or 
two yearly HbA1c EQA surveys, rather than the maximum 
of four, had patients with on average 0.17% higher HbA1c 
levels (0.06, 0.28) (1.8 mmol/mol [0.6, 3.1]). For each unit 
increase in the GP offices’ HbA1c POC analytical trueness 
score, the patients’ HbA1c levels were lower by 0.04% 
HbA1c (−0.09, −0.001) (−0.5 mmol/mol [−1.0, −0.01]).
Conclusions: Novel use of validated patient data in 
 combination with laboratory EQA data showed that 
patients consulting GPs in offices that perform HbA1c POC 
testing, participate in HbA1c EQA surveys, and maintain 
good analytical quality have lower HbA1c levels. Accurate 
HbA1c POC results, available during consultations, may 
improve diabetes care.
Keywords: glycemic control; hemoglobin A1c;  point-of-care 
testing; primary care; type 2 diabetes.
Introduction
In diabetes, good glycemic control and aggressive treat-
ment of cardiovascular risk factors reduce the risk of 
macro- and microvascular complications [1, 2]. It has been 
debated whether hemoglobin A1c (HbA1c) point-of-care 
(POC) testing, defined as “any form of laboratory testing 
that takes place outside of the conventional or central 
laboratory” [3], can improve glycemic control in diabetes. 
POC testing has the advantage of producing a test result 
within minutes. While a 2011 systematic review and meta-
analysis concluded there was absence of evidence for the 
effectiveness of POC testing for HbA1c in diabetes manage-
ment [4], more recent reviews have concluded that HbA1c 
POC testing does lower HbA1c levels, presumably by allow-
ing the patient and doctor to discuss the test result during 
the visit, which can lead to changes in treatment without 
delay, enhance compliance, and motivate for  lifestyle 
changes [5, 6]. The underlying evidence, however, is 
somewhat scarce. Some studies find no effect of POC [7, 8]. 
Others are small [9] or short-term randomized controlled 
trials [10, 11] investigating initial effects of  introducing 
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POC testing. Others are set in countries with limited 
resources or lack of universal health care [12, 13], where 
HbA1c levels are generally high. Any effects of POC testing 
in such settings may not be generalizable.
In Norway, primary health care is usually provided 
by small groups of general practitioners (GPs) working 
together, sharing personnel and laboratory facilities (GP 
offices). Since the country is sparsely populated, trans-
portation of blood samples to central laboratories can be 
challenging. POC testing, however, is widely available for 
a variety of analytes, including HbA1c for diagnosis and fol-
low-up of patients with diabetes. The Norwegian Organiza-
tion for Quality Improvement of Laboratory Examinations 
(Noklus) has provided quality systems for POC testing in 
primary care since 1992 [14]. In addition to education, site 
visits, and instrument evaluations, Noklus offers external 
quality assurance (EQA) schemes for many analytes. The 
analytical quality of POC testing improves over time with 
Noklus participation [15, 16], and for several HbA1c POC 
instruments, the analytical quality in primary care has been 
shown to be comparable to that of hospital laboratories [17].
By linking data from Noklus with data on more than 
20,000 patients with type 2 diabetes, our aim was to 
 investigate whether availability of HbA1c POC testing in GP 
offices was associated with glycemic control. In  addition, 
we aimed to investigate if participation in HbA1c EQA 
surveys and analytical quality of the HbA1c POC testing 
were associated with the patients’ HbA1c levels, which, to 
our knowledge, has not previously been investigated.
Materials and methods
Data sources
The Norwegian Diabetes Register for Adults was established in 2006 
as a consent-based national quality registry [18]. It is updated annu-
ally and collects information on test results, treatments, procedures, 
and vascular complications by extracting data from patients’ elec-
tronic medical records. During 2014–2017, more than 19,000 patients 
with type 2 diabetes followed up by GPs were registered on at least 
one occasion.
The ROSA 4  study is a collaboration between Noklus, 
 Stavanger University Hospital, Nordland Hospital in Bodø, and 
the Universities of Bergen and Oslo. The study is the fourth wave 
of a population-based, cross-sectional multi-center study to 
assess the quality of diabetes care in general practice in Norway 
[19]. GPs in five  geographically diverse Norwegian counties were 
invited to  participate, and a total of 282 GPs in 77 GP offices agreed 
to  contribute data. Information on test results, treatments, proce-
dures, and vascular complications from 2014  was extracted from 
approximately 11,500 diabetes patients’ electronic medical records 
by trained study nurses.
Noklus is a national nonprofit foundation which has provided 
quality systems, including EQA schemes, to laboratories in Norway 
since 1992 [14]. In 2018, Noklus had 1690 participating GP offices 
(99% national participation rate). Noklus has detailed information 
on which EQA schemes each GP office subscribes to, which POC 
equipment they use, and analytical quality over time.
Study population and study variables
Data from The Norwegian Diabetes Register for Adults and the 
ROSA 4 study were collected using almost identical procedures. To 
ensure comparability in time, we used data from the registry col-
lected during 2014–2017. We used one record per patient – the most 
recent where an HbA1c result was included. There was a substantial 
overlap between patients registered in the two data sources. When 
we had data on a patient from both sources, and from the same 
year, we used the data from ROSA 4. For each patient, we extracted 
information on year of birth, sex, years since diagnosis, smoking 
status, ethnicity, body mass index (BMI), HbA1c level, when they 
last had a monofilament test performed (a simple screening test 
designed to detect possible or definite peripheral neuropathy, a risk 
factor for diabetic foot ulcers), and most recent referral to an oph-
thalmologist.
Noklus offers four HbA1c EQA surveys per year, and both GP 
offices and hospital laboratories participate. For details on EQA 
materials, target values, etc., see Solvik et al. [17]. In short, for each 
EQA survey, the participants receive two samples of 500 μL (two lev-
els: normal and elevated) of freshly drawn pooled EDTA whole blood 
from 8 to 10 persons with and without diabetes. The target value for 
each sample is assigned by the European Reference Laboratory for 
Glycohemoglobin (Winterswijk, The Netherlands). EQA participants 
analyze each sample in duplicate, usually on consecutive days. 
Noklus evaluates EQA participant performance as “good”, “accept-
able”, or “poor” based on pre-defined algorithms (for details, see 
Supplementary Methods). During the study period, the HbA1c unit 
used by Norwegian laboratories was % HbA1c (NGSP units).
If a GP office subscribed to the HbA1c EQA program a given year, 
we assumed that the patients’ HbA1c levels had been measured using 
their POC instrument. To differentiate analytical quality, we con-
structed a “trueness score” based on EQA participant performance, 
awarding a score of 2 for a good result, 1 for an acceptable result, and 
0 for a poor result. A score of 0 was also given if precision was consid-
ered too poor to allow evaluation of trueness. Since each survey had 
two levels, and there were four surveys in a year, a maximum yearly 
score of 16 could be achieved. We adjusted the score by dividing it 
by the participant’s actual number of HbA1c EQA survey participa-
tions that year (1–4). Thus, a maximum trueness score of 4 could be 
achieved, and a minimum of 0.
We also calculated trueness scores for other POC analyses per-
formed by many GP offices, namely urine albumin-creatinine ratio, 
CRP and hemoglobin, for which twice-yearly EQA surveys are offered 
by Noklus.
Statistical methods
Since patients treated by the same GP on average receive more 
similar care than patients treated by different GPs, and GPs 
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working together probably practice medicine more similarly than 
GPs  working in  different environments, we used general and 
 generalized linear mixed models to analyze the data and account 
for clustering. Random effects (random intercepts) were allowed for 
each GP office, and for each GP within a GP office. The patient’s 
individual characteristics were used as level 1 fixed effects, the GP 
characteristics as level 2 fixed effects, and the GP office character-
istics as level 3 fixed effects. All statistical analyses were performed 
using R version 3.5.1 (www.r-project.org/about.html) with packages 
“tidyverse” and “lme4”.
Our main outcome measure was individual patient HbA1c 
 levels, and our exposures were (i) if the GP office performed HbA1c 
POC  testing (yes/no), and in the subset that did; (ii) the frequency 
of HbA1c EQA survey participations in a year (1–2, 3, or 4 [reference]); 
and (iii) average yearly trueness score (0–4). The final two expo-
sures were investigated simultaneously in the same models. Thus, 
all patients who had their HbA1c level recorded the same year, and 
who were followed up by GPs working together in the same GP office, 
had the same exposures. We adjusted for the following potential con-
founders in the models: patient age (in years), years since diagnosis, 
sex, smoking status (daily smoker vs. not), ethnicity (non-European 
vs. European), proportion of female type 2 diabetes patients for a 
GP, and where relevant also type of POC instrument (“Afinion” [by 
Abbott, reference], “DCA” [by Siemens] or other).
Similarly, we investigated if POC testing for urine albumin- 
creatinine ratio, CRP, and hemoglobin were associated with HbA1c 
levels. Also, we investigated if HbA1c POC testing was associated 
with whether the recommended monofilament test had been per-
formed the same year as HbA1c was measured, or the previous year 
(yes/no), and if the patient had been referred to an ophthalmolo-
gist the same year as HbA1c was measured, or during the previous 
1–2 years (yes/no).
To check for interactions, we included interaction terms 
between exposures and other potential explanatory variables in the 
models, as well as a variable indicating patient data source (Dia-
betes Register or ROSA 4  study). Interaction terms with a p-value 
of <0.10 assessed by likelihood ratio tests when comparing models 
with and without the interaction term were further evaluated by 
stratification.
The analyses were pre-specified and performed according to 
plan.
Ethical considerations
The study protocol was approved by the Western Norway Regional 
Ethical Committee (2018/1778/REK Vest).
Results
We received data on 19,336 type 2 diabetes patients from 
the Diabetes Register for Adults and 10,356 from the ROSA 
4  study. After removing records lacking an HbA1c result, 
or with HbA1c recorded prior to 2014, duplicates (individu-
als present in both data sources), and records lacking 
information on GP, we had information on 22,778 unique 
individuals with type 2 diabetes followed up in primary 
care, who had had their HbA1c level recorded during 
2014–2017 (Figure 1).
A total of 1267 GPs from 393 GP offices contributed 
data to the Diabetes Register and/or the ROSA 4  study 
(Table 1). Patients from the registry were on average older, 
had a longer diabetes duration, were more likely to be of 
European origin, and less likely to be daily smokers than 
patients from the ROSA 4 study. Patients from the registry 
were also more likely to have had their BMI recorded, a 
monofilament test performed, and having been referred 
to an ophthalmologist. Women, on average, had slightly 
lower HbA1c levels than men (−0.08% HbA1c, 95% confi-
dence interval [−0.11, −0.05], −0.9 mmol/mol [−1.2, −0.5]), 
and non-Europeans higher HbA1c levels than Europe-
ans (0.13% HbA1c [0.08, 0.18], 1.4 mmol/mol [0.9, 2.0]) 
( Supplementary Table 1).
Three hundred and sixty-five out of 393 GP offices 
(93%) performed HbA1c POC testing, and “Afinion” (Abbott) 
was the most commonly used instrument (Table 1). More 
than 80% of GP offices participated in all four HbA1c EAQ 
surveys offered in a year, and median trueness score was 
high (3.25 of 4 in 2014 and 3.75 of 4 in 2017).
A total of 878 patients were followed up by GPs who 
did not perform HbA1c POC testing the year the patient’s 
HbA1c level was recorded. Adjusted for potential confound-
ers, these patients, on average, had 0.15% higher levels of 
HbA1c (0.04, 0.27) (1.7 mmol/mol [0.5, 2.9], Table 2). For the 
21,900 individuals followed up by GPs who did perform 
HbA1c POC testing, the GP offices’ frequency of HbA1c 
EQA participations was associated with patients’ HbA1c 
levels. If the GP office had participated in three HbA1c EQA 
surveys during the year rather than four, the patients had 
HbA1c levels that were on average 0.05% HbA1c (0.001, 
0.11) higher (0.6 mmol/mol [0.01, 1.2]). If the GP office had 
participated in only one or two surveys, the patients had 
HbA1c levels that were on average 0.17% HbA1c (0.06, 0.28) 
higher (1.8  mmol/mol [0.6, 3.1]). Analytical quality was 
also important; for each unit increase in the GP offices’ 
analytical trueness scores, the patients’ HbA1c levels were 
lower by 0.04% HbA1c (−0.09, −0.001) (−0.5  mmol/mol 
[−1.0, −0.01]).
The association between HbA1c POC testing and 
HbA1c level varied with smoking status (p-for interaction 
0.06). When GPs performed POC testing, HbA1c levels 
in  non-smokers were lower by 0.13 % HbA1c (0.01, 0.24) 
(1.4 mmol/mol HbA1c [0.1, 2.6]), while for smokers, HbA1c 
levels were lower by 0.25% HbA1c (0.03, 0.48) (2.8 mmol/
mol [0.3, 5.3]). Effects of exposure variables did not vary 
by patient data source, type of POC instrument, patient 
sex, or ethnicity.
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Sensitivity analyses
Since hospital laboratories also participate in Noklus 
HbA1c EQA surveys, we could compare analytical quality 
between primary care POC and hospital laboratory 
methods. We found no systematic differences that could 
explain the association between availability of POC 
testing and lower HbA1c levels (Supplementary Table 2 and 
 Supplementary Figure 1).
In Noklus HbA1c EQA surveys, level 2 is above 6.5% 
HbA1c (48  mmol/mol). When pooling bias (partici-
pants’ level 2 result minus reference value) for all EQA 
 participants and all 16  surveys during 2014–2017, we 
observed that poor performers on average measured lower 
than the target value, rather than higher (Supplementary 
Figure 2). Thus, any possible systematic bias in measure-
ments could not explain why poor performers had patients 
with higher HbA1c levels.
Sixty-one percent of patients had had the recom-
mended monofilament test, and 63% had been referred 
to an ophthalmologist (Table 1). Whether or not the GP 
performed HbA1c POC testing was not associated with the 
patient’s odds of having had a monofilament test (odds 
ratio [OR] 0.78, 95% CI [0.41, 1.48]) or having been referred 
to an ophthalmologist (OR 1.10, [0.81, 1.49]). However, 
for patients followed up by GPs who did perform HbA1c 
POC testing, the odds of having had a monofilament 
test increased with increasing analytical trueness score 
(OR 1.18, [1.02, 1.35]), and so did the odds of having been 
referred to an ophthalmologist (OR 1.18, [1.06, 1.31]).
Further, we investigated if GP office participation in 
other POC EQA schemes was associated with patients’ 
HbA1c levels. Frequency of participation and obtained 
analytical trueness score in EQA surveys for the analytes 
hemoglobin, CRP, or urine albumin-creatinine ratio were 
not associated with patients’ HbA1c levels (Supplemen-
tary Table 3). However, as Noklus offers only two yearly 
EQA surveys for these analytes, compared to four for 
HbA1c, we had less statistical power to detect potential 
differences.
Discussion
By novel use of validated patient data from Norwegian 
GPs linked with laboratory data from Noklus EQA surveys, 
we found that the availability of HbA1c POC testing, fre-
quency of participation in HbA1c EQA surveys, and good 
analytical quality were all associated with lower levels of 
HbA1c in type 2 diabetes patients treated in primary care. 
Better analytical quality was also associated with higher 
patients’ odds of having had a monofilament test done 
and having been referred to an ophthalmologist.
While some investigators have found no associations 
between availability of HbA1c POC testing and HbA1c levels 
in patients with diabetes [7, 8], many have [9–13]. These 
Datasource 1:
The Norwegian Diabetes Register
for Adults – 19,336 individuals
Datasource 2:
The ROSA 4 study-
10,356 individuals
29,692 records
HbA1c missing (n = 819)
Duplicate record (n = 4473)
HbA1c recorded prior to 2014  (n = 925)







GP office did not offer HbA1c
point-of-care testing (n = 878)
For analyses of HbA1c point-of-care
(yes/no) as exposure
For analyses of analytical quality and
frequency of external quality assessment
survey participations as exposures
Figure 1: Study population.
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studies are, however, generally not directly comparable 
to ours. Some are randomized controlled trials (RCTs) 
with limited follow up time [10, 11] lacking the ability to 
demonstrate lasting effects. Others are conducted in lower 
resource settings than Norwegian primary care, where 
HbA1c levels are high to begin with and a lot is to be gained 
from any intervention [9, 11, 12]. Also, to our knowledge, 
no one has previously investigated if EQA participation or 
the analytical quality of the POC testing is associated with 
patient HbA1c levels.
Table 1: Individual- and GP office characteristics, overall and stratified by data source and year.
  Total   Norwegian Diabetes 
Register for Adults
  ROSA 4 study
Individuals, n (%)   22,778 (100)   18,014 (79.1)   4764 (20.9)
GPs, n   1267   1216   278
GP offices, n   393   383   76
Individual patient characteristics
 Median HbA1c (10–90th percentile)
  HbA1c, %   6.9 (5.9–8.5)   6.9 (5.9–8.4)   6.8 (5.8–8.7)
  HbA1c, mmol/mol   52 (41–69)   52 (41–68)   51 (40–72)
 Age, years, median (10–90th percentile)   67 (49–82)   67 (50–82)   65 (47–82)
 Years since diagnosis
  Median (10–90th percentile)   8 (1–20)   9 (1–20)   7 (1–18)
  Percent missing   4.0   3.0   8.1
 Percent female   43.7   43.0   46.4
 Percent non-European   12.1   10.5   18.5
 Percent daily smokers   16.2   15.7   18.1
 Body mass index (BMI)
  Median (10–90th percentile)   29.0 (23.4–36.8)   29.0 (23.4–36.7)   29.2 (23.5–38.7)
  Percent missing   21.8   11.1   62.2
 Monofilament test performed, n (%)   13,922 (61)   13,160 (73)   762 (16)
 Referral to ophthalmologist, n (%)   14,416 (63)   11,994 (67)   2422 (51)
 Year of HbA1c measurement (%)
  2014   25.0   5.1   100.0
  2015   15.6   19.7   0.0
  2016   19.6   24.8   0.0
  2017   39.9   50.4   0.0
GP office characteristics 2014
 Median number of GPs contributing data (10–90th percentile)  2 (1–5)   2 (1–4)   3.5 (1–6)
 HbAc POC available (%)   167/176 (95)   100/106 (94)   73/76 (96)
 Type of instrument (%)
  Afinion   112 (67)   70 (70)   47 (64)
  DCA   55 (33)   30(30)   26 (36)
 HbA1c EQA participations (%)
  1–2   7 (4)   3(3)   4 (5)
  3   23 (14)   16 (16)   9 (12)
  4   137 (82)   81 (81)   60 (82)
 Median trueness score (0–4), (10–90th percentile)   3.25 (2.75–4.00)   3.25 (2.75–4.00)   3.5 (2.67–4.00)
GP office characteristics 2017
 Median number of GPs contributing data (10–90th percentile)    3 (1–5)  
 HbA1c POC available (%)     238/257 (93)  
 Type of instrument (%)
  Afinion     128 (54)  
  DCA     106 (45)  
  Other     4 (2)  
 HbA1c EQA participations (%)
  1–2     5 (2)  
  3     38 (16)  
  4     195 (82)  
 Median trueness score (0–4), (10–90th percentile)     3.75 (3.00–4.00)  
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A more comparable study to ours in setting was a ret-
rospective US observational study from 2001–2005. HbA1c 
levels for approximately 2500 patients in a diabetes clinic 
were followed before and after introduction of HbA1c POC 
testing [13]. Compared to 2000 patients with stable HbA1c 
levels who were followed-up in a family practice without 
HbA1c POC testing, patients in the diabetes clinic saw a 
significant decline in HbA1c levels, beginning 1 year after 
the introduction of HbA1c POC testing and still evident after 
3.5 years. However, the authors did not discuss potential 
systematic differences between POC and hospital methods, 
nor was quality control of the methods described.
In our study, reflecting real-life follow up of type 2 
diabetes patients in primary care, most were cared for by 
GPs performing HbA1c POC testing. Those who were not, 
however, had higher HbA1c levels. We also found that 
the GP offices’ frequency of participation in HbA1c EQA 
surveys, as well as their actual analytical quality, dem-
onstrated by the results in the HbA1c EQA surveys, were 
associated with their patients’ HbA1c levels. The type of 
POC instrument used did not explain the results, nor were 
the effects significantly different depending on type of 
instrument used. We found no evidence to suggest that 
systematic measurement bias or differences between POC 
and hospital methods could explain these findings. This 
is supported by a 2017 meta-analysis, which did not find 
overall systematic differences between the two most com-
monly used HbA1c POC instruments in Norway and various 
hospital comparator methods [20]. Having high quality 
HbA1c POC analysis available in the GP office makes an 
accurate test result available during the consultation. 
This could be associated with lower patient HbA1c levels 
because it allows the patient and doctor to discuss the test 
result during the visit and make the correct clinical deci-
sions and necessary adjustments together, thereby opti-
mizing treatment.
We also observed that GP offices with good analyti-
cal quality of their HbA1c POC testing had patients who 
were more likely to have been screened for vascular com-
plications in accordance with guidelines. Therefore, an 
alternative interpretation of our findings could be that in 
general, good analytical quality in the laboratory could be 
a marker of a well-organized GP office, where patients are 
more likely to be followed up according to guidelines and 
receive better overall care, resulting also in lower HbA1c 
levels. However, since we found no associations between 
the analytical quality of other POC tests and HbA1c levels, 
albeit with somewhat lower statistical power, this may be 
an indication that high quality HbA1c POC testing itself 
facilitates better diabetes care, lowering HbA1c levels.
It is indisputable that the absolute differences in 
HbA1c levels we detect are small. However, the risk of 
complications in diabetes increase with HbA1c levels, and 
there is no threshold value. In a population, many people 
subject to a small risk can generate more illness than the 
few people at high risk [21]. Therefore, to shift the whole 
population to a somewhat lower risk level (the population-
based approach), may have a more substantial impact on 
population health than the conventional clinical high-risk 
approach. Thus, the clinical implications of the differ-
ences in HbA1c detected in our study could be important 
on a population level.
An important strength of our study is the novel use 
of validated patient data in combination with laboratory 
data from EQA surveys. This allowed strict control of the 
overall analytical quality of the HbA1c measurements for 
POC instruments as well as hospital instruments. More 
importantly, it means our study reflects the actual every-
day care that diabetes patients in primary care in Norway 
receive. The results are not due to any initial effect follow-
ing the introduction of an intervention, which can be the 
case in an RCT. Another important strength is the large 
Table 2: Estimated absolute differences in patients’ HbA1c levels by GP offices’ availability of point-of-care (POC) testing for HbA1c, frequency 
of yearly HbA1c external quality assessment (EQA) survey participations, and analytical quality (trueness score).
 
 
HbA1c (%) (95% CI) 
 
HbA1c (mmol/mol) (95% CI)
Crudea  Adjustedb Crudea  Adjustedb
POC for HbA1c
 Yes vs. no   −0.12 (−0.23, −0.005)  −0.15 (−0.27, −0.04)  −1.3 (−2.5, −0.05)  −1.7 (−2.9, −0.5)
Frequency of HbA1c EQA survey participation
 3 vs. 4   0.07 (0.01, 0.12)  0.05 (0.001, 0.11)  0.8 (0.2, 1.3)  0.6 (0.01, 1.2)
 1–2 vs. 4   0.14 (0.03, 0.25)  0.17 (0.06, 0.28)  1.5 (0.3, 2.8)  1.8 (0.6, 3.1)
Trueness score (per unit increase, 0–4)   −0.03 (−0.07, 0.02)  −0.04 (−0.09, −0.001)  −0.3 (−0.8, 0.2)  −0.5 (−1.0, −0.01)
aAccounted for clustering by GP and GP office as random intercepts in the models. bIn addition to random effects, adjusted for the following 
fixed effects: patient age (in years), years since diagnosis, sex, smoking status (daily smoker vs. not), ethnicity (non-European vs. 
European), proportion of female type 2 diabetes patients, and type of POC instrument where relevant (Afinion [reference], DCA or other).
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study population of more than 20,000 patients with type 
2 diabetes. Also, since our exposures and outcomes were 
obtained from different data sources, any misclassifica-
tion will be non-differential and, if anything, bias effect 
estimates towards the null.
One potential limitation of the study is that patients 
from the Diabetes Register may not be representative of 
the population of Norwegian type 2 diabetes patients. In 
2017, approximately 15% of Norwegian GPs submitted data 
to the registry, and they are likely to be more interested in 
diabetes care, and therefore treat their patients according 
to guidelines. Although GPs also had to consent to partici-
pation in the ROSA 4 study, they represent a more random 
selection of Norwegian GPs, and hence their patients are 
likely to be more representative of Norwegian type 2 dia-
betes patients. However, in our study population, average 
HbA1c levels were very similar in the two data sources, as 
were other patient characteristics. Also, we did not find any 
indication of effects of exposures varying with patient data 
source. Therefore, combining the data sources to achieve 
the largest study population possible seemed reasonable.
Another potential limitation is that we had only the 
most recent record of HbA1c for each patient. For a sub-
group of patients from the registry, there are more than 
one HbA1c record available. However, since HbA1c POC 
testing was widespread in Norwegian GP offices long 
before the start of the study period in 2014, it is unlikely 
that we would have been able to identify any substantial 
individual effects on HbA1c levels from introduction of 
HbA1c POC testing in a longitudinal study design. Finally, 
even though we were able to account for several possible 
confounders in our models, and clustering by GP and GP 
office, residual confounding cannot be excluded.
In conclusion, we found that GP offices’ availability 
and good analytical quality of HbA1c POC testing, as well 
as participation in HbA1c EQA surveys, were all associated 
with better glycemic control in a large population of type 
2 diabetes patients. Having an accurate HbA1c test result 
available during the consultation may facilitate better dia-
betes care.
Author contributions: All authors have accepted responsi-
bility for the entire content of this submitted manuscript 
and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organizations played 
no role in the study design; in the collection, analysis, and 
interpretation of the data; in the writing of the report; or in 
the decision to submit the report for publication.
References
1. UK Prospective Diabetes Study (UKPDS) Group. Intensive 
 blood-glucose control with sulphonylureas or insulin compared 
with conventional treatment and risk of complications in patients 
with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
2. Eeg-Olofsson K, Zethelius B, Gudbjornsdottir S, Eliasson B, 
Svensson AM, Cederholm J. Considerably decreased risk of 
cardiovascular disease with combined reductions in HbA1c, 
blood pressure and blood lipids in type 2 diabetes: report from 
the Swedish National Diabetes Register. Diab Vasc Dis Res 
2016;13:268–77.
3. St John A, Price CP. Point-of-care testing. In: Rifai N, Horvath 
AR, Wittwer CT, editors. Tietz textbook of clinical chemistry and 
molecular diagnostics. 6th Ed. St. Louis, MO: Elsevier, 2018:371.
4. Al-Ansary L, Farmer A, Hirst J, Roberts N, Glasziou P,  
Perera R, et al. Point-of-care testing for HbA1c in the management 
of diabetes: a systematic review and metaanalysis. Clin Chem 
2011;57:568–76.
5. Schnell O, Crocker JB, Weng J. Impact of HbA1c testing at point 
of care on diabetes management. J Diabetes Sci Technol 
2017;11:611–7.
6. Florkowski C, Don-Wauchope A, Gimenez N, Rodriguez-Capote K, 
Wils J, Zemlin A. Point-of-care testing (POCT) and evidence-based 
laboratory medicine (EBLM) – does it leverage any advantage in 
clinical decision making? Crit Rev Clin Lab Sci 2017;54:471–94.
7. Kennedy L, Herman WH, Strange P, Harris A, Team GA. Impact 
of active versus usual algorithmic titration of basal insulin 
and point-of-care versus laboratory measurement of HbA1c on 
glycemic control in patients with type 2 diabetes: the Glycemic 
Optimization with Algorithms and Labs at Point of Care (GOAL A1C) 
trial. Diabetes Care 2006;29:1–8.
8. Khunti K, Stone MA, Burden AC, Turner D, Raymond NT, Burden 
M, et al. Randomised controlled trial of near-patient testing for 
glycated haemoglobin in people with type 2 diabetes mellitus. 
Br J Gen Pract 2006;56:511–7.
9. Rust G, Gailor M, Daniels E, McMillan-Persaud B, Strothers H, 
Mayberry R. Point of care testing to improve glycemic control. Int 
J Health Care Qual Assur 2008;21:325–35.
10. Bubner TK, Laurence CO, Gialamas A, Yelland LN, Ryan P, Willson 
KJ, et al. Effectiveness of point-of-care testing for therapeutic 
control of chronic conditions: results from the PoCT in General 
Practice Trial. Med J Aust 2009;190:624–6.
11. Thaler LM, Ziemer DC, Gallina DL, Cook CB, Dunbar VG, Phillips 
LS, et al. Diabetes in urban African-Americans. XVII. Availability 
of rapid HbA1c measurements enhances clinical decision-making. 
Diabetes Care 1999;22:1415–21.
12. Motta LA, Shephard MD, Brink J, Lawson S, Rheeder P. Point-of-
care testing improves diabetes management in a primary care 
clinic in South Africa. Prim Care Diabetes 2017;11:248–53.
13. Petersen JR, Finley JB, Okorodudu AO, Mohammad AA, Grady 
JJ, Bajaj M. Effect of point-of-care on maintenance of glycemic 
control as measured by A1C. Diabetes Care 2007;30:713–5.
14. Stavelin A, Sandberg S. Harmonization activities of Noklus – a 
quality improvement organization for point-of-care laboratory 
examinations. Clin Chem Lab Med 2018;57:106–14.
15. Bukve T, Roraas T, Riksheim BO, Christensen NG, Sandberg S. 
Point-of-care urine albumin in general practice offices: effect 
of participation in an external quality assurance scheme. Clin 
Chem Lab Med 2015;53:45–51.
1356      Tollånes et al.: HbA1c point-of-care testing and glycemic control
16. Bukve T, Stavelin A, Sandberg S. Effect of participating in 
a quality improvement system over time for point-of-care 
C-reactive protein, glucose, and hemoglobin testing. Clin Chem 
2016;62:1474–81.
17. Solvik UO, Roraas T, Christensen NG, Sandberg S. Diag-
nosing diabetes mellitus: performance of hemoglobin A1c 
 point-of-care instruments in general practice offices. Clin Chem 
2013;59:1790–801.
18. Cooper J, Thue G, Claudi T, Lovaas K, Carlsen S, Sandberg S. The 
Norwegian Diabetes Register for Adults – an overview of the first 
years. Norsk Epidemiologi 2013;23:6.
19. Bakke A, Cooper JG, Thue G, Skeie S, Carlsen S, Dalen I, et al. 
Type 2 diabetes in general practice in Norway 2005–2014: 
 moderate improvements in risk factor control but still major 
gaps in complication screening. Br Med J Open Diabetes Res 
Care 2017;5:e000459.
20. Hirst JA, McLellan JH, Price CP, English E, Feakins BG,  
Stevens RJ, et al. Performance of point-of-care HbA1c test 
devices:  implications for use in clinical practice – a sys-
tematic review and meta-analysis. Clin Chem Lab Med 
2017;55:167–80.
21. Rose G. Some implications of population changes. In: The 
 strategy of preventive medicine. New York, USA: Oxford Univer-
sity Press, 1992:74.
Supplementary Material: The online version of this article offers 
supplementary material (https://doi.org/10.1515/cclm-2020-0026).
